Chronic Hypersecretory COPD with Mucus Plugging

Chronic hypersecretory COPD with mucus plugging represents a distinct phenotype within COPD where pathological mucus hyperproduction and impaired clearance lead to persistent intraluminal mucus plugs that obstruct medium and small airways. Quantitative CT studies have demonstrated that mucus plugs are common and clinically meaningful—their presence in ≥3 segments associates with FEV₁ decline 78 mL/year (vs 38 mL/year without plugs), increased exacerbation frequency, worse symptoms, and higher mortality independent of FEV₁.

Pathophysiology involves multiple interacting mechanisms: airway epithelial remodeling with goblet cell metaplasia (increased MUC5AC and MUC5B production driven by IL-13, IL-1β, EGFR signaling), submucosal gland hyperplasia, neutrophilic inflammation with MMP-9 and MMP-12 protease activity, ciliary dysfunction with reduced ciliary beat frequency, dehydrated airway surface liquid (ENaC overactivity, CFTR dysfunction in some patients), and chronic bacterial infection (Pseudomonas, Haemophilus, Streptococcus) further driving mucus production. Smoking is the primary trigger but persistence after cessation is common due to established epithelial remodeling.

Diagnosis combines clinical chronic bronchitis criteria (productive cough most days for ≥3 months × 2 consecutive years) with imaging evidence (quantitative CT mucus plug score, bronchial wall thickening) and physiologic assessment. Treatment beyond standard COPD therapy includes mucolytics (N-acetylcysteine 600-1200 mg/day, erdosteine 600 mg/day showing modest exacerbation reduction; carbocysteine), expectorants and hydration, inhaled hypertonic saline (3-7%) in selected cases, airway clearance techniques (active cycle breathing, oscillating PEP devices, high-frequency chest wall oscillation), bronchoscopic mucus extraction in critical lobar/segmental obstruction, antibiotics during exacerbations targeting bacterial colonizers, dual/triple inhaled bronchodilator therapy, ICS in eosinophilic overlap (≥300 eosinophils), azithromycin prophylaxis (250 mg three times weekly), and emerging biologics targeting type 2 inflammation. Smoking cessation remains paramount.